Filtered By:
Condition: Ischemic Stroke
Drug: Angiomax

This page shows you your search results in order of date.

Order by Relevance | Date

Total 31 results found since Jan 2013.

Anticoagulation strategies in COVID-19 infected patients receiving ECMO support
CONCLUSION: In hospitalized patients with COVID-19-associated acute respiratory distress syndrome (ARDS) on VV ECMO support, the use of bivalirudin showed to be a viable anticoagulation alternative in terms of efficacy compared to UFH and resulted in a favorable safety profile with lower rates of bleeding and thrombotic events.PMID:37682210 | DOI:10.1051/ject/2023027
Source: Journal of Extra-Corporeal Technology - September 8, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Dayne Diaz Jenny Martinez Grant Bushman William R Wolowich Source Type: research

Bivalirudin or Unfractionated Heparin for Anticoagulation in Pediatric Patients on Continuous Flow Ventricular Assist Device Support: Single-Center Retrospective Cohort Study
Conclusions: Use of bivalirudin for anticoagulation in patients on CF-VAD support was associated with lesser odds of hemorrhagic complications compared with use of UFH. Bivalirudin “washout” was successful in medical management of six of eight cases of possible pump thrombosis.
Source: Pediatric Critical Care Medicine - October 1, 2022 Category: Pediatrics Tags: Online Cardiac Intensive Care Source Type: research

Outcomes of systemic anticoagulation with bivalirudin for Impella 5.0
Int J Artif Organs. 2021 Jul 12:3913988211032238. doi: 10.1177/03913988211032238. Online ahead of print.ABSTRACTTemporary mechanical circulatory support (tMCS) devices are used for the management of cardiogenic shock. The Impella 5.0 (Abiomed; Danvers, MA) (IMP5) is a commonly used, surgically implanted, tMCS device that requires systemic anticoagulation and purge solution to avoid pump failure. To avoid heparin-induced thrombocytopenia (HIT) from unfractionated heparin (UFH) use, our program has explored the utility of bivalirudin (BIV) for systemic anticoagulation in IMP5. This single center, retrospective study included...
Source: The International Journal of Artificial Organs - July 12, 2021 Category: Transplant Surgery Authors: Carly Fabrizio Marissa N Levito Ryan Rivosecchi Michael Bashline Brittany Slocum Arman Kilic Catalin Toma Holt Murray Raj Ramanan Jeffrey Fowler Gavin W Hickey Edward T Horn Source Type: research

Heparin-Induced Thrombocytopenia after Total Knee Replacement.
Authors: Salášek M, Šlechtová J, Pavelk T Abstract Heparin-induced thrombocytopenia is a rare complication of treatment with both unfractionated heparin (UFH) and low molecular weight heparin (LMWH). Antibodies against the complex heparin-platelet factor 4 are the main cause of pathogenesis, resulting in the activation of thrombocytes, coagulation, endothelium, monocytes, neutrophils and subsequent highly prothrombotic state. The prothrombotic state can result not only in venous but also in arterial thrombosis at different locations (which is manifested apart from venous thromboembolic disease also by acute lim...
Source: Acta Chirurgiae Orthopaedicae et Traumatologiae Cechoslovaca - May 13, 2020 Category: Orthopaedics Tags: Acta Chir Orthop Traumatol Cech Source Type: research